| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
44,500,000 |
| Market
Cap: |
198.47(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.39 - $11.83 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile uniQure is engaged in the field of gene therapy, focusing to develop single treatments for patients suffering from genetic and other diseases. Co. is developing etranacogene dezaparvovec, a gene therapy for patients with hemophilia B that is designed to restore Factor IX (FIX) activity, a protein for blood clotting. Etranacogene dezaparvovec includes an adeno-associated virus (AAV) 5 vector incorporating the FIX-Padua variant. Co. is also developing AMT-180 for hemophilia A, AMT-190 for fabry disease, and AMT-130 for huntington's disease. Co.'s AMT-150 is a one-time, intrathecally-administered, AAV gene therapy incorporating Co.'s miQURE™ silencing technology.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
28,404 |
81,669 |
102,627 |
249,047 |
| Total Sell Value |
$143,555 |
$483,399 |
$698,702 |
$3,966,152 |
| Total People Sold |
11 |
12 |
13 |
14 |
| Total Sell Transactions |
11 |
14 |
16 |
52 |
| End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Balachandran Madhavan |
Director |
– • – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,230 |
8,022 |
|
- |
|
| Soteropoulos Paula |
Director |
– • – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,230 |
21,144 |
|
- |
|
| Schaffer David |
Director |
– • – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,230 |
46,931 |
|
- |
|
| Van Deventer Sander |
Chief Scientific Officer |
• – – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
I/I |
16,502 |
41,571 |
|
- |
|
| Springhorn Jeremy P. |
Director |
– • – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,230 |
8,022 |
|
- |
|
| Meek David D. |
Director |
– • – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,230 |
3,230 |
|
- |
|
| Mcmillan Scott T. |
Chief Operating Officer |
• – – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
15,870 |
21,023 |
|
- |
|
| Kuta Alexander Edward Iii |
SVP, Regulatory Affairs |
• – – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
18,644 |
27,630 |
|
- |
|
| Klemt Christian |
Chief Accounting Officer |
• – – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
17,564 |
57,564 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2019-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
69,349 |
509,113 |
|
- |
|
| Schaffer David |
Director |
– • – |
2019-01-17 |
4 |
AS |
$30.71 |
$230,325 |
D/D |
(7,500) |
43,701 |
|
- |
|
| Klemt Christian |
Chief Accounting Officer |
• – – |
2019-01-03 |
4 |
S |
$27.91 |
$160,175 |
D/D |
(5,739) |
40,000 |
|
- |
|
| Astley-Sparke Philip |
Director |
– • – |
2018-12-03 |
4 |
AS |
$30.39 |
$151,950 |
D/D |
(5,000) |
23,252 |
|
- |
|
| Gut Robert |
Chief Medical Officer |
• – – |
2018-09-18 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
35,000 |
|
- |
|
| Zelenkofske Steven |
Chief Medical Officer |
• – – |
2018-06-06 |
4 |
S |
$37.14 |
$888,723 |
D/D |
(23,929) |
159,458 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2018-03-15 |
4 |
S |
$21.72 |
$850,751 |
D/D |
(39,169) |
439,764 |
|
- |
|
| Kaye Jack |
Director |
– • – |
2018-01-29 |
4 |
S |
$18.53 |
$53,329 |
D/D |
(2,878) |
12,914 |
|
- |
|
| Soteropoulos Paula |
Director |
– • – |
2018-01-29 |
4 |
S |
$18.53 |
$53,329 |
D/D |
(2,878) |
17,914 |
|
- |
|
| Van Deventer Sander |
Chief Scientific Officer |
• – – |
2018-01-29 |
4 |
S |
$18.53 |
$110,902 |
I/I |
(5,985) |
25,069 |
|
- |
|
| Astley-Sparke Philip |
Director |
– • – |
2018-01-29 |
4 |
S |
$18.53 |
$121,186 |
D/D |
(6,540) |
28,252 |
|
- |
|
| Schaffer David |
Director |
– • – |
2018-01-29 |
4 |
S |
$18.53 |
$53,329 |
D/D |
(2,878) |
15,314 |
|
- |
|
| Van Deventer Sander |
Chief Scientific Officer |
• – – |
2018-01-26 |
4 |
A |
$0.00 |
$0 |
I/I |
7,795 |
31,054 |
|
- |
|
| Zelenkofske Steven |
Chief Medical Officer |
• – – |
2018-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
8,387 |
183,387 |
|
- |
|
| Kapusta Matthew C |
CEO, CFO, Managing Director |
• • – |
2018-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
31,374 |
478,933 |
|
- |
|
| Firuta Paul E |
Chief Commercial Officer |
• – – |
2018-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
8,566 |
93,817 |
|
- |
|
336 Records found
|
|
Page 12 of 14 |
|
|
0.08 (1.76%) 
